1973-76 Resident and Registrar in Internal Medicine, St.Vincent's Hospital, Melbourne, Australia
1976-77 Clinical Research Registrar to Dr. I. R. Mackay, Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
1977-78 Gastroenterology Registrar, St. Vincent's Hospital, Melbourne, Australia
1978-80 Clinical Research Fellow in Hepatology to Dr. T. B. Reynolds, University of Southern California, Los Angeles, CA
1980-83 Visiting Fogarty Fellow to Dr. A.S. Fauci, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD
1983-85 Visiting Staff Fellow to Liver Diseases Section, National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD
American Board of Internal Medicine, Internal Medicine
UCSF Liver Center
Member, UCSF Immunology Graduate Program
UCSF Helen Diller Family Comprehensive Cancer Center
Alcoholic Liver Disease
Benign Liver Tumors
Fulminant Hepatic Failure
Hepatocellular Carcinoma (Liver Cancer)
Live Donor Liver Transplantation
Nonalcoholic Fatty Liver Disease
Primary Biliary Cirrhosis
Primary Sclerosing Cholangitis
Liver Injury and Repair
Viral hepatitis and the role of the host immune response.
Dr. Marion Peters is a Professor of Medicine and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of transgenic mouse models of liver specific T cell responses, HIV and HCV coinfection, and alcohol and HCV infection.
Dr. Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital, Melbourne, University of Southern California and National Institutes of Health. She was Chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998.
My major interest is in viral hepatitis and the role of the host immune response. My work focuses on interactions among alcohol use, cannabis use and HIV co-infection on fibrotic outcomes of HCV infection. We are currently evaluating the predictors of progression of liver disease in HIV and HCV coinfected women within the Women's Interagency HIV Study (WIHS): the role of alcohol, cannabis, HIV status and control as well as reproductive aging on the severity and rate of progression of liver disease.
We are also studying adherence to antiretroviral therapy in HIV/HCV co-infected women and on HCV-specific and innate immune responses in persons co-infected with HCV and HIV. I work within the AIDS Clinical Trial Group to develop clinical trials in viral hepatitis and HIV and within the Women's Interagency HIV Study (WIHS) to examine predictors of liver-related morbidity and mortality in a cohort of women with HIV/HCV infection.
Most recent publications from a total of 130
Geha R, Peters M, Gill RM, Dhaliwal G. Histology Rings True. N Engl J Med. 2017 03 02; 376(9):869-874. View in PubMed
Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. HIV-infected and Uninfected Adults with Non-Genotype 3 Hepatitis C Virus Have Less Hepatic Steatosis than Adults with Neither Infection. Hepatology. 2016 Dec 16. View in PubMed
Kardashian A, Ma Y, Scherzer R, Price JC, Sarkar M, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Sex differences in the association of HIV infection with hepatic steatosis. AIDS. 2016 Nov 7. View in PubMed
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis. 2016 Nov 1; 63(9):1160-1167. View in PubMed
Desai SN, Dodge JL, Landay AL, Glesby MJ, Latham PS, Villacres MC, French AL, Gange SJ, Greenblatt RM, Peters MG. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study. Medicine (Baltimore). 2016 Aug; 95(33):e4483. View in PubMed
French AL, Hotton A, Young M, Nowicki M, Augenbraun M, Anastos K, Seaberg E, Rosenberg W, Peters MG. Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. J Acquir Immune Defic Syndr. 2016 Jul 1; 72(3):274-80. View in PubMed
Valcour VG, Rubin LH, Obasi MU, Maki PM, Peters MG, Levin S, Crystal HA, Young MA, Mack WJ, Cohen MH, Pierce CB, Adimora AA, Tien PC. Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C. J Acquir Immune Defic Syndr. 2016 Jul 1; 72(3):266-73. View in PubMed
Kelly EM, Dodge JL, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG. Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus-coinfected Women. Clin Infect Dis. 2016 Aug 15; 63(4):512-8. View in PubMed
Beck KR, Pantilat SZ, O'Riordan DL, Peters MG. Use of Palliative Care Consultation for Patients with End-Stage Liver Disease: Survey of Liver Transplant Service Providers. J Palliat Med. 2016 Aug; 19(8):836-41. View in PubMed
Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. AIDS Res Hum Retroviruses. 2016 Jul; 32(7):660-7. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.